AKT1 and non-small cell lung carcinoma: Taken together, our data supported the possibility that PI3K-Akt may be a crucial target of SH003 for NSCLC treatment and Therefore, our data suggest that the PI3K-Akt pathway may be a crucial target of SH003 for NSCLC treatment and further investigations are necessary to confirm the pharmacological mechanisms of SH003 and its key compounds.